Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-06-27 pm EDT
213.57 USD   +0.77%
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
MT
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wedbush Trims Biogen's Price Target to $185 From $188, Citing Aduhelm Wind-Down, Maintains Neutral Rating

05/04/2022 | 05:04am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about BIOGEN INC.
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
MT
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Index
CI
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Index
CI
06/22Biogen, Happify Health Team Up to Offer Digital Services for Multiple Sclerosis Patient..
MT
06/22Biogen Inc. - European Patent Office Grants Patent Related to TECFIDERA (Dimethyl Fumar..
AQ
06/22Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital..
BU
06/22Biogen and Happify Health Collaborates to Support Multiple Sclerosis Patients on Digita..
CI
06/21BIOGEN INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote o..
AQ
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 9 831 M - -
Net income 2022 1 994 M - -
Net cash 2022 60,0 M - -
P/E ratio 2022 15,1x
Yield 2022 -
Capitalization 31 278 M 31 278 M -
EV / Sales 2022 3,18x
EV / Sales 2023 2,98x
Nbr of Employees 9 610
Free-Float 85,5%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 211,93 $
Average target price 242,78 $
Spread / Average Target 14,6%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-11.67%31 038
CSL LIMITED-6.70%90 814
SAMSUNG BIOLOGICS CO.,LTD.-10.74%45 825
WUXI BIOLOGICS (CAYMAN) INC.-16.59%41 498
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-12.56%24 084
UCB-19.34%16 152